Results Highlights

Key Results (Table)

Consolidated Financial Data(JPY billion / % change)

  FY2008 FY2009 FY2010 FY2011 FY2012
Net Sales 955.9 1,084.3 1,127.6 1,154.6 1,218.1
3.0% 13.4% 4.0% 2.4% 5.5%
Operating Income 91.5 98.5 126.3 148.7 169.7
-22.6% 7.6% 28.2% 17.7% 14.1%
Ordinary Income 96.1 109.1 128.4 152.1 184.5
-22.6% 13.5% 17.7% 18.5% 21.3%
Net Income 47.1 67.4 82.4 92.2 122.4
-23.9% 43.2% 22.1% 11.9% 32.8%
Research and Development
Expenditure
135.9 151.8 164.7 159.2 192.4
33.5% 11.7% 8.4% -3.3% 20.8%
  FY2008 FY2009 FY2010 FY2011 FY2012
Total Assets 1,298.8 1,458.4 1,589.7 1,666.8 1,779.2
Net Assets 863.8 948.5 1,163.3 1,222.8 1,325.1
Equity Capital Ratio 62.3 64.2 72.4 72.5 73.7

From 1QFY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate.The method of presentation for upfront licensing payments received was changed from non-operating income to net sales.Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Geographical Segment Sales

  FY2012 (JPY billion) % of Net Sales
Japan 595.3 48.9
North America 445.7 36.6
Others 177.1 14.5

Sales by Business Segment

  FY2012 (JPY billion) % of Net Sales
Pharmaceutical business 850.9 69.8
Nutraceutical business 246.9 20.3
Consumer products business   45.2   3.7
Other business   75.0   6.2

Key Management Indicators

  FY2008 FY2009 FY2010 FY2011 FY2012
ROE (Return on equity: %) 7.2 7.7 7.9 7.8 9.7
EPS (Earnings per share: yen) 2,727.2 143.5 164.5 165.2 221.9
Annual dividends per share (yen) 250.0 12.5 28.0 45.0 58.0
Payout ratio (%) 9.2% 8.7% 17.3% 27.2% 26.1%
* On June 30, 2009, a twenty-for-one stock split was executed by way of a free share distribution.